Latest / Community Health Media
Dr. Megan Kruse & Dr. Carol Tweed – ESR1 Mutation Monitoring & Oral SERDs in Metastatic Breast Cancer
Are we moving past the traditional "wait for progression" model in HR+ mBC? In this episode of CHM Conversations, Dr. Megan Kruse and Dr. Carol Tweed examine how molecular resistance monitoring is redefining the treatment timeline.
The discussion highlights the shift toward a proactive approach, focusing on the clinical utility of serial ctDNA testing as seen in the SERENA-6 trial. Dr. Kruse and Dr. Tweed discuss how identifying ESR1 mutations early allows for a more precise transition to oral SERDs, helping to preserve endocrine sensitivity and delay the need for more aggressive ADC or…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.